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We read with great interest the article published recently by 
Kartalis et al [1]. Our study group investigated the application 
of fl uorescence with the use of nanoparticles as a novel hybrid 
imaging method of pancreatic neuroendocrine tumors 
(pNETs). We demonstrated that a novel biomarker, namely 
calreticulin (CRT), is present in pNETs and may be targeted 
with fl uorescent gold quantum dots (AuQDs).
CRT is a ubiquitous Ca2+-binding protein with chaperone 
activity and a rather complex relation to various cancers: its 
overexpression is positively associated with various solid 
tumors, usually as an adverse prognostic indicator [2]; however, 
contrary to its positive correlation to tumorigenesis and poor 
cancer prognosis, CRT also seems to promote immunogenic 
cancer cell death.
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QDs are semiconductor nanocrystals with unique optical 
properties, such as highly tuneable fl uorescence and high 
photochemical stability; their relatively large surface-to-mass 
ratio enables them to perform as antibody or drug-carriers, 
attributes that provide QDs with an almost unlimited potential 
in cancer theranostics [3]. Our group have synthesized AuQDs 
with functionalized groups and bio-conjugated to anti-
calreticulin polyclonal antibodies (AuQD-antiCRT). Th ese 
AuQDs were manufactured to emit at 800  nm on excitation 
in the near infrared (NIR). It can be shown that conjugated 
AuQDs can be targeted specifi cally to in vitro pancreatic 
adenocarcinoma cell lines and ex vivo human pancreatic 
lesions. With Human Research Authority approval (REC 
Reference: 04/q0504/1) and appropriate patient consenting, 
paired tissue samples from resected pancreatic specimens 
post-pancreatectomy were obtained and stored in liquid 
nitrogen. Sections were then cut on a cryostat-microtome at 
approximately -25°C and mounted on Vectabond coated slides 
for observation under laser scanning confocal fl uorescence 
microscopy (LSCM, Nikon Eclipse TE 300). Once the fi xed 
tissues were characterized under the LSCM, selected paired 
slides were incubated with AuQD-antiCRT and observed 
under the LSCM. Th e resected pancreatic specimens were 
further processed and evaluated by a senior histopathologist.
Among the subjects was a 61-year-old female who 
underwent a Whipple’s procedure for what proved to be 
a completely resected, well diff erentiated neuroendocrine 
neoplasm, TNM stage pT3N1pMx. Th e photomicrographs 
of the pathological tissues under laser excitation before and 
aft er incubation to AuQD-antiCRT are depicted in Fig.  1. 
Illustrations (A) and (B) were captured by LSCM aft er 543 nm 
green laser beam excitation via a 650  nanometres/Long 
Pass (nm/LP) fl uorescence barrier, while (C) and (D) aft er 
488  nm blue and 650 nm/LP fi ltering. Th ere was minimal 
signal emission aft er 543  nm excitation due to lower energy 
confi rming NIR emission (A). Post-incubation with AuQD-
antiCRT (B), there was NIR emission (pseudocolor) in 650/LP 
fi lter cut-off  and therefore CRT expression. Images (C) and 
(D) also demonstrate NIR fl uorescence aft er AuQD-antiCRT 
incubation, more intense upon He-Ne (488  nm). Th ese two 
latter photographs also demonstrate some of the architectural 
appearances typical of pNETs, such as the cell nests (single 
arrows), trabeculi (double arrows) and gyriform patterns 
(arrowheads).
To the authors’ best knowledge, this is the fi rst pictorial 
demonstration of CRT surface expression on pancreatic 
neuroendocrine malignancy with the use of fl uorescent quantum 
nanotechnology and tracing of pNETs with bio-stable, non-
degradable fl uorophores, such as the AuQDs. Th ese fi ndings 
may facilitate further in vivo investigation on CRT expression on 
pNETs and on the application of QD–based theranostics on the 
detection and treatment of these conditions [4]. Finally, these 
fi ndings should trigger the design of in vivo animal studies on 
the fl uorescence-guided laparoscopic surgery (FGLS) aft er QD-
labeling of CRT-rich solid pancreatic lesions [5]. Th e advantages 
of FGLS have already been described by Metildi et al [6]; the 
theranostic advantage of QD-fl uorophores as both diagnostic 
and therapeutic tracers and carriers of immunochemical 
tumoricidal agents and their safety for in vivo applications in 
the treatment of pNETs are yet to be developed and proven.
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Figure 1 Laser scanning confocal fl uorescence microscopy 
photomicrographs illustrating a pancreatic neuroendocrine tumor 
before and aft er exposure to fl uorescent gold quantum dots  bio-
conjugated to anti-calreticulin polyclonal antibodies
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